Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GPB versus placebo in corticobasal syndrome
2022-002988-30Phase 2Active
- Sponsor
- Klinikum rechts der Isar
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in corticobasal degeneration (CBD) comparing Glycerol phenylbutyrate with Placebo (2 arms). Primary endpoint: Longitudinal change in plasma neurofilament light chain. Started Dec 2022; status: active.
02
Drugs
glycerol phenylbutyrate
03
Conditions
corticobasal degeneration (CBD)
Beyond the preview
Go deeper on 2022-002988-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002988-30.